PGZ.F Healius Limited
- Market cap
- EUR 241M
- P/E
- -
- P/B
- 2.12x
- ROE
- -242.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is PGZ.F undervalued?
Graham numberThe Graham number of Healius Limited cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Healius Limited fundamental analysis
No fundamental analysis for Healius Limited yet.
Healius Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Healius Limited
Healius Limited provides medical laboratory and pathology services in Australia. The company provides services under the Laverty Pathology, Dorevitch Pathology, Western Diagnostic Pathology, Genomic Diagnostic, Vetnostics Pathology, QML Pathology, TML Pathology, Abbott Pathology, IQ Pathology, Kossard, Gastrolab Dermatopathology, and Agilex Biolabs brands. It operates medical laboratories and patient collection centers. The company was formerly known as Primary Health Care L…
Full company profileHealius Limited financial statements
Healius Limited annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 1.66B | 1.74B | 1.80B | 1.58B | 1.90B | 2.34B | 1.71B | 1.75B | 1.34B | 1.37B |
| Gross Profit | 1.48B | 1.54B | 1.60B | 1.38B | 1.63B | 2.02B | 1.48B | 1.52B | 1.13B | 1.17B |
| Operating Income | 82.8M | 70.4M | 112M | 73.4M | 243M | 488M | 98.1M | 65.5M | 200K | 30.2M |
| EBITDA | -333M | 180M | 186M | 264M | 469M | 711M | -91.5M | -339M | -342M | -146M |
| Net Income | -517M | 4.10M | 55.9M | -70.5M | 43.7M | 308M | -368M | -646M | -151M | -416M |
| EPS | -0.96 | 0.01 | 0.09 | -0.11 | 0.07 | 0.54 | -0.65 | -0.89 | -0.21 | -0.57 |
| Balance Sheet | ||||||||||
| Total Assets | 3.11B | 3.13B | 3.35B | 4.57B | 3.78B | 4.14B | 3.65B | 2.98B | 1.78B | 1.42B |
| Total Liabilities | 1.25B | 1.31B | 1.30B | 2.64B | 1.92B | 2.22B | 2.15B | 1.94B | 1.19B | 1.25B |
| Shareholders' Equity | 1.87B | 1.82B | 2.06B | 1.93B | 1.86B | 1.92B | 1.51B | 1.04B | 588M | 172M |
| Cash & Short-term Investments | 95.5M | 84.0M | 120M | 138M | 70.1M | 81.3M | 115M | 60.1M | 57.2M | 67.2M |
| Cash Flow | ||||||||||
| Operating Cash Flow | 212M | 202M | 128M | 407M | 526M | 587M | 333M | - | - | - |
| Capital Expenditure | 74.5M | 57.0M | 79.6M | 49.3M | 48.4M | 81.4M | 62.7M | 64.0M | 65.9M | 43.3M |
| Free Cash Flow | 92.6M | 129M | 27.6M | 267M | 465M | 493M | 257M | 203M | 220M | 168M |
| Ratios | ||||||||||
| ROE | -27.7% | 0.2% | 2.7% | -3.7% | 2.4% | 16.0% | -24.4% | -62.1% | -25.7% | -242.3% |
| ROA | -16.6% | 0.1% | 1.7% | -1.5% | 1.2% | 7.4% | -10.1% | -21.7% | -8.5% | -29.3% |
| Net Profit Margin | -31.2% | 0.2% | 3.1% | -4.4% | 2.3% | 13.2% | -21.5% | -37.0% | -11.2% | -30.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Healius Limited dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- May 9, 2025
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | - | - | - |
| 2025 | AUD 300M | 0.41 | - |
| 2024 | - | - | - |
| 2023 | AUD 34.3M | 0.06 | - |
| 2022 | AUD 98.1M | 0.17 | 31.9% |
| 2021 | AUD 56.3M | 0.09 | 128.8% |
| 2020 | EUR 21.2M | 0.03 | - |
| 2019 | EUR 52.3M | 0.08 | 93.6% |
| 2018 | EUR 56.9M | 0.11 | 1,387.8% |
| 2017 | EUR 58.4M | 0.11 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Healius Limited
- Insiders 2.51%
- Institutions 97.49%
- Public & others 0.00%
- Shares outstanding 726M
- Free float 562M
Healius Limited company profile
- Company name
- Healius Limited
- Ticker
- PGZ.F
- ISIN
- AU0000033359
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 3,343
- Fiscal year end
- June
- Address
- 161 Castlereagh Street, Sydney, NSW, Australia, 2000
- Phone
- 61 2 9432 9400
- Website
- healius.com.au
About Healius Limited
Healius Limited provides medical laboratory and pathology services in Australia. The company provides services under the Laverty Pathology, Dorevitch Pathology, Western Diagnostic Pathology, Genomic Diagnostic, Vetnostics Pathology, QML Pathology, TML Pathology, Abbott Pathology, IQ Pathology, Kossard, Gastrolab Dermatopathology, and Agilex Biolabs brands. It operates medical laboratories and patient collection centers. The company was formerly known as Primary Health Care Limited and changed its name to Healius Limited in December 2018. Healius Limited was incorporated in 1994 and is based in Sydney, Australia.
Healius Limited management
10- Mr. Paul D. Anderson B.Com., C.A.MD, CEO & Director
- Mr. Andrew ThomsonCFO & Company Secretary
- Mr. Puneet Nagi M.B.A.Chief Operating Officer
- Mr. Prasad AravGroup Executive of Digital & Technology and Strategy
- Sharon NgHead of FP&A and Investor Relations
- Ms. Kylie BrownGroup General Counsel, Company Secretary & Chief Risk Officer
- Ms. Paula BaylissGroup Executive of People & Culture
- Mr. John McKechnieAdvisor
- Dr. Phil LucasChief Executive of Lumus Imaging
- Ian McphanChief Operating Officer of Healius Pathology